Author:
Hoffmann A.-C.,Schuler M.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733–2743
2. Press MF, Pike MC, Hung G et al. (1994) Amplification and overexpression of HER-2/neu in carcinomas of thesalivary gland: correlation with poor prognosis. Cancer Res, 54: 5675–5682
3. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353: 1673–1684
4. MacGregor JI, JordanVC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev, 50: 151–196
5. Bonneterre J, Thurlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol, 18: 3748–3757